Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Eriksson

Showing results (461-470 of 1,235) with videos related to

Pageof 124
Sort By:
BMJ (Clinical Research Ed.)|April 3, 2001
Prenatal growth and subsequent marital status: longitudinal studyD I Phillips, D J Handelsman, J G Eriksson, et al.
Thrombosis Research|November 15, 2002
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosisKarin Wåhlander, Leif Lapidus, Carl-Gustav Olsson, et al.
Clinical Pharmacokinetics|July 9, 2003
Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatranUlf G Eriksson, Susanne Johansson, Per-Ola Attman, et al.
Clinical Drug Investigation|May 23, 2007
Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgeryDavid Bergqvist, Jan-Helge Solhaug, Lena Holmdahl, et al.
European Journal of Public Health|April 3, 2018
Morbidity and housing status 10 years after shelter use-follow-up of homeless men in Helsinki, FinlandAgnes Stenius-Ayoade, Peija Haaramo, Hannu Kautiainen, et al.
Medicine and Science in Sports and Exercise|February 6, 2007
Physical activity, diet, and incident diabetes in relation to an ADRA2B polymorphismDavid E Laaksonen, Niina Siitonen, Jaana Lindström, et al.
Critical Reviews in Toxicology|April 24, 2019
Computational modeling of lung deposition of inhaled particles in chronic obstructive pulmonary disease (COPD) patients: identification of gaps in knowledge and dataKoustav Ganguly, Ulrika Carlander, Estella Dg Garessus, et al.
International Journal of Epidemiology|September 22, 2012
The placental origins of sudden cardiac deathDavid J P Barker, Gail Larsen, Clive Osmond, et al.
Aging Cell|March 10, 2025
Associations Between Leisure-Time Physical Activity and Metabolomics-Based Markers of Biological Aging in Late Midlife: Short-Term and Long-Term Follow-UpKatri Ruutu, Niko S Wasenius, Kothandaraman Narasimhan, et al.
Clinical Pharmacokinetics|May 13, 2003
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatranTroy C Sarich, Renli Teng, Gary R Peters, et al.
Pageof 124

Showing results (461-470 of 1,235) with videos related to

Sort By:
Pageof 124
BMJ (Clinical Research Ed.)|April 3, 2001
Prenatal growth and subsequent marital status: longitudinal studyD I Phillips, D J Handelsman, J G Eriksson, et al.
Thrombosis Research|November 15, 2002
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosisKarin Wåhlander, Leif Lapidus, Carl-Gustav Olsson, et al.
Clinical Pharmacokinetics|July 9, 2003
Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatranUlf G Eriksson, Susanne Johansson, Per-Ola Attman, et al.
Clinical Drug Investigation|May 23, 2007
Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgeryDavid Bergqvist, Jan-Helge Solhaug, Lena Holmdahl, et al.
European Journal of Public Health|April 3, 2018
Morbidity and housing status 10 years after shelter use-follow-up of homeless men in Helsinki, FinlandAgnes Stenius-Ayoade, Peija Haaramo, Hannu Kautiainen, et al.
Medicine and Science in Sports and Exercise|February 6, 2007
Physical activity, diet, and incident diabetes in relation to an ADRA2B polymorphismDavid E Laaksonen, Niina Siitonen, Jaana Lindström, et al.
Critical Reviews in Toxicology|April 24, 2019
Computational modeling of lung deposition of inhaled particles in chronic obstructive pulmonary disease (COPD) patients: identification of gaps in knowledge and dataKoustav Ganguly, Ulrika Carlander, Estella Dg Garessus, et al.
International Journal of Epidemiology|September 22, 2012
The placental origins of sudden cardiac deathDavid J P Barker, Gail Larsen, Clive Osmond, et al.
Aging Cell|March 10, 2025
Associations Between Leisure-Time Physical Activity and Metabolomics-Based Markers of Biological Aging in Late Midlife: Short-Term and Long-Term Follow-UpKatri Ruutu, Niko S Wasenius, Kothandaraman Narasimhan, et al.
Clinical Pharmacokinetics|May 13, 2003
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatranTroy C Sarich, Renli Teng, Gary R Peters, et al.
Pageof 124